#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The development of flow processes has gained tremendous interest in recent years in organic chemistry due to numerous advantages of such types of processes over classic batch approaches .
2-1	16-19	The	abstract[2]	new[2]	coref	3-27[19_2]
2-2	20-31	development	abstract[2]	new[2]	_	_
2-3	32-34	of	abstract[2]	new[2]	_	_
2-4	35-39	flow	abstract[2]|abstract|abstract[4]	new[2]|new|new[4]	coref|coref	2-24[0_4]|3-30
2-5	40-49	processes	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-6	50-53	has	_	_	_	_
2-7	54-60	gained	_	_	_	_
2-8	61-71	tremendous	abstract[5]	new[5]	coref	6-5[48_5]
2-9	72-80	interest	abstract[5]	new[5]	_	_
2-10	81-83	in	_	_	_	_
2-11	84-90	recent	time[6]	new[6]	coref	8-2[69_6]
2-12	91-96	years	time[6]	new[6]	_	_
2-13	97-99	in	_	_	_	_
2-14	100-107	organic	abstract[7]	new[7]	_	_
2-15	108-117	chemistry	abstract[7]	new[7]	_	_
2-16	118-121	due	_	_	_	_
2-17	122-124	to	_	_	_	_
2-18	125-133	numerous	abstract[8]	new[8]	coref	3-7[15_8]
2-19	134-144	advantages	abstract[8]	new[8]	_	_
2-20	145-147	of	abstract[8]	new[8]	_	_
2-21	148-152	such	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-22	153-158	types	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-23	159-161	of	abstract[8]|abstract[9]	new[8]|new[9]	_	_
2-24	162-171	processes	abstract[8]|abstract[9]|abstract	new[8]|new[9]|giv	coref	3-30[21_0]
2-25	172-176	over	abstract[8]	new[8]	_	_
2-26	177-184	classic	abstract[8]|abstract[12]	new[8]|new[12]	_	_
2-27	185-190	batch	abstract[8]|abstract|abstract[12]	new[8]|new|new[12]	coref	6-40
2-28	191-201	approaches	abstract[8]|abstract[12]	new[8]|new[12]	_	_
2-29	202-203	.	_	_	_	_

#Text=In addition to higher efficiency and safety advantages , the ability to ensure constant product quality has turned out to be a major driving force for the development of flow processes .
3-1	204-206	In	_	_	_	_
3-2	207-215	addition	_	_	_	_
3-3	216-218	to	_	_	_	_
3-4	219-225	higher	abstract[13]	new[13]	_	_
3-5	226-236	efficiency	abstract[13]	new[13]	_	_
3-6	237-240	and	_	_	_	_
3-7	241-247	safety	abstract|abstract[15]	new|giv[15]	_	_
3-8	248-258	advantages	abstract[15]	giv[15]	_	_
3-9	259-260	,	_	_	_	_
3-10	261-264	the	abstract[16]	new[16]	_	_
3-11	265-272	ability	abstract[16]	new[16]	_	_
3-12	273-275	to	abstract[16]	new[16]	_	_
3-13	276-282	ensure	abstract[16]	new[16]	_	_
3-14	283-291	constant	abstract[16]|abstract[17]	new[16]|new[17]	_	_
3-15	292-299	product	abstract[16]|abstract[17]	new[16]|new[17]	_	_
3-16	300-307	quality	abstract[16]|abstract[17]	new[16]|new[17]	_	_
3-17	308-311	has	_	_	_	_
3-18	312-318	turned	_	_	_	_
3-19	319-322	out	_	_	_	_
3-20	323-325	to	_	_	_	_
3-21	326-328	be	_	_	_	_
3-22	329-330	a	abstract[18]	new[18]	_	_
3-23	331-336	major	abstract[18]	new[18]	_	_
3-24	337-344	driving	abstract[18]	new[18]	_	_
3-25	345-350	force	abstract[18]	new[18]	_	_
3-26	351-354	for	abstract[18]	new[18]	_	_
3-27	355-358	the	abstract[18]|abstract[19]	new[18]|giv[19]	_	_
3-28	359-370	development	abstract[18]|abstract[19]	new[18]|giv[19]	_	_
3-29	371-373	of	abstract[18]|abstract[19]	new[18]|giv[19]	_	_
3-30	374-378	flow	abstract[18]|abstract[19]|abstract|abstract[21]	new[18]|giv[19]|giv|giv[21]	coref|coref	4-56|4-56[39_21]
3-31	379-388	processes	abstract[18]|abstract[19]|abstract[21]	new[18]|giv[19]|giv[21]	_	_
3-32	389-390	.	_	_	_	_

#Text=In particular , for active pharmaceutical ingredients ( APIs ) , this aspect is important , as the FDA along with the EPA , as the respective institutions in United States and Europe for approval of medicines , added aspects of continuous manufacturing to their guidelines , whereas for a long time the focus of flow processes was on “ classic ” chemical processes with , for example , hazardous and thermally labile substances and chemocatalytic reactions .
4-1	391-393	In	_	_	_	_
4-2	394-404	particular	_	_	_	_
4-3	405-406	,	_	_	_	_
4-4	407-410	for	_	_	_	_
4-5	411-417	active	substance[22]	new[22]	_	_
4-6	418-432	pharmaceutical	substance[22]	new[22]	_	_
4-7	433-444	ingredients	substance[22]	new[22]	_	_
4-8	445-446	(	_	_	_	_
4-9	447-451	APIs	abstract	new	_	_
4-10	452-453	)	_	_	_	_
4-11	454-455	,	_	_	_	_
4-12	456-460	this	abstract[24]	new[24]	_	_
4-13	461-467	aspect	abstract[24]	new[24]	_	_
4-14	468-470	is	_	_	_	_
4-15	471-480	important	_	_	_	_
4-16	481-482	,	_	_	_	_
4-17	483-485	as	_	_	_	_
4-18	486-489	the	organization[25]	new[25]	_	_
4-19	490-493	FDA	organization[25]	new[25]	_	_
4-20	494-499	along	organization[25]	new[25]	_	_
4-21	500-504	with	_	_	_	_
4-22	505-508	the	organization[26]	new[26]	_	_
4-23	509-512	EPA	organization[26]	new[26]	_	_
4-24	513-514	,	_	_	_	_
4-25	515-517	as	_	_	_	_
4-26	518-521	the	organization[27]	new[27]	ana	4-45[0_27]
4-27	522-532	respective	organization[27]	new[27]	_	_
4-28	533-545	institutions	organization[27]	new[27]	_	_
4-29	546-548	in	organization[27]	new[27]	_	_
4-30	549-555	United	organization[27]|place[28]	new[27]|new[28]	_	_
4-31	556-562	States	organization[27]|place[28]	new[27]|new[28]	_	_
4-32	563-566	and	organization[27]	new[27]	_	_
4-33	567-573	Europe	organization[27]|place	new[27]|new	_	_
4-34	574-577	for	organization[27]	new[27]	_	_
4-35	578-586	approval	organization[27]|event[30]	new[27]|new[30]	_	_
4-36	587-589	of	organization[27]|event[30]	new[27]|new[30]	_	_
4-37	590-599	medicines	organization[27]|event[30]|substance	new[27]|new[30]|new	_	_
4-38	600-601	,	_	_	_	_
4-39	602-607	added	_	_	_	_
4-40	608-615	aspects	abstract[32]	new[32]	_	_
4-41	616-618	of	abstract[32]	new[32]	_	_
4-42	619-629	continuous	abstract[32]|abstract[33]	new[32]|new[33]	_	_
4-43	630-643	manufacturing	abstract[32]|abstract[33]	new[32]|new[33]	_	_
4-44	644-646	to	_	_	_	_
4-45	647-652	their	organization|abstract[35]	giv|new[35]	_	_
4-46	653-663	guidelines	abstract[35]	new[35]	_	_
4-47	664-665	,	_	_	_	_
4-48	666-673	whereas	_	_	_	_
4-49	674-677	for	_	_	_	_
4-50	678-679	a	time[36]	new[36]	_	_
4-51	680-684	long	time[36]	new[36]	_	_
4-52	685-689	time	time[36]	new[36]	_	_
4-53	690-693	the	abstract[37]	new[37]	_	_
4-54	694-699	focus	abstract[37]	new[37]	_	_
4-55	700-702	of	abstract[37]	new[37]	_	_
4-56	703-707	flow	abstract[37]|abstract|abstract[39]	new[37]|giv|giv[39]	coref|coref	4-60[40_39]|5-5
4-57	708-717	processes	abstract[37]|abstract[39]	new[37]|giv[39]	_	_
4-58	718-721	was	_	_	_	_
4-59	722-724	on	_	_	_	_
4-60	725-726	“	abstract[40]	giv[40]	coref	5-5[44_40]
4-61	727-734	classic	abstract[40]	giv[40]	_	_
4-62	735-736	”	abstract[40]	giv[40]	_	_
4-63	737-745	chemical	abstract[40]	giv[40]	_	_
4-64	746-755	processes	abstract[40]	giv[40]	_	_
4-65	756-760	with	abstract[40]	giv[40]	_	_
4-66	761-762	,	abstract[40]	giv[40]	_	_
4-67	763-766	for	abstract[40]	giv[40]	_	_
4-68	767-774	example	abstract[40]	giv[40]	_	_
4-69	775-776	,	abstract[40]	giv[40]	_	_
4-70	777-786	hazardous	abstract[40]|substance[41]	giv[40]|new[41]	_	_
4-71	787-790	and	abstract[40]|substance[41]	giv[40]|new[41]	_	_
4-72	791-800	thermally	abstract[40]|substance[41]	giv[40]|new[41]	_	_
4-73	801-807	labile	abstract[40]|substance[41]	giv[40]|new[41]	_	_
4-74	808-818	substances	abstract[40]|substance[41]	giv[40]|new[41]	_	_
4-75	819-822	and	abstract[40]	giv[40]	_	_
4-76	823-837	chemocatalytic	abstract[40]|event[42]	giv[40]|new[42]	coref	12-12[112_42]
4-77	838-847	reactions	abstract[40]|event[42]	giv[40]|new[42]	_	_
4-78	848-849	.	_	_	_	_

#Text=Recently , biocatalysis in flow processes has become an emerging field with an increasing number of examples .
5-1	850-858	Recently	_	_	_	_
5-2	859-860	,	_	_	_	_
5-3	861-873	biocatalysis	_	_	_	_
5-4	874-876	in	_	_	_	_
5-5	877-881	flow	abstract|abstract[44]	giv|giv[44]	coref|coref	6-11|8-13[74_44]
5-6	882-891	processes	abstract[44]	giv[44]	_	_
5-7	892-895	has	_	_	_	_
5-8	896-902	become	_	_	_	_
5-9	903-905	an	_	_	_	_
5-10	906-914	emerging	_	_	_	_
5-11	915-920	field	_	_	_	_
5-12	921-925	with	_	_	_	_
5-13	926-928	an	abstract[45]	new[45]	_	_
5-14	929-939	increasing	abstract[45]	new[45]	_	_
5-15	940-946	number	abstract[45]	new[45]	_	_
5-16	947-949	of	abstract[45]	new[45]	_	_
5-17	950-958	examples	abstract[45]|abstract	new[45]|new	coref	6-31[59_0]
5-18	959-960	.	_	_	_	_

#Text=An enzymatic reaction of particular interest for an application in flow mode due to its matured technology level is asymmetric ketone reduction , having a proven track record underlined by many successful examples demonstrated in the past for the batch mode .
6-1	961-963	An	abstract[47]	new[47]	coref	6-20[56_47]
6-2	964-973	enzymatic	abstract[47]	new[47]	_	_
6-3	974-982	reaction	abstract[47]	new[47]	_	_
6-4	983-985	of	abstract[47]	new[47]	_	_
6-5	986-996	particular	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
6-6	997-1005	interest	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
6-7	1006-1009	for	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
6-8	1010-1012	an	abstract[47]|abstract[48]|abstract[49]	new[47]|giv[48]|new[49]	coref	10-13[87_49]
6-9	1013-1024	application	abstract[47]|abstract[48]|abstract[49]	new[47]|giv[48]|new[49]	_	_
6-10	1025-1027	in	abstract[47]|abstract[48]|abstract[49]	new[47]|giv[48]|new[49]	_	_
6-11	1028-1032	flow	abstract[47]|abstract[48]|abstract[49]|abstract|abstract[51]	new[47]|giv[48]|new[49]|giv|new[51]	ana|coref	6-15[0_51]|8-13
6-12	1033-1037	mode	abstract[47]|abstract[48]|abstract[49]|abstract[51]	new[47]|giv[48]|new[49]|new[51]	_	_
6-13	1038-1041	due	abstract[47]	new[47]	_	_
6-14	1042-1044	to	abstract[47]	new[47]	_	_
6-15	1045-1048	its	abstract[47]|abstract|abstract[54]	new[47]|giv|new[54]	coref	6-39[62_0]
6-16	1049-1056	matured	abstract[47]|abstract[54]	new[47]|new[54]	_	_
6-17	1057-1067	technology	abstract[47]|abstract|abstract[54]	new[47]|new|new[54]	_	_
6-18	1068-1073	level	abstract[47]|abstract[54]	new[47]|new[54]	_	_
6-19	1074-1076	is	_	_	_	_
6-20	1077-1087	asymmetric	abstract[56]	giv[56]	coref	10-20[91_56]
6-21	1088-1094	ketone	substance|abstract[56]	new|giv[56]	coref	9-13
6-22	1095-1104	reduction	abstract[56]	giv[56]	_	_
6-23	1105-1106	,	abstract[56]	giv[56]	_	_
6-24	1107-1113	having	abstract[56]	giv[56]	_	_
6-25	1114-1115	a	abstract[56]|abstract[58]	giv[56]|new[58]	_	_
6-26	1116-1122	proven	abstract[56]|abstract[58]	giv[56]|new[58]	_	_
6-27	1123-1128	track	abstract[56]|place|abstract[58]	giv[56]|new|new[58]	_	_
6-28	1129-1135	record	abstract[56]|abstract[58]	giv[56]|new[58]	_	_
6-29	1136-1146	underlined	abstract[56]|abstract[58]	giv[56]|new[58]	_	_
6-30	1147-1149	by	abstract[56]|abstract[58]	giv[56]|new[58]	_	_
6-31	1150-1154	many	abstract[56]|abstract[58]|abstract[59]	giv[56]|new[58]|giv[59]	coref	8-9[71_59]
6-32	1155-1165	successful	abstract[56]|abstract[58]|abstract[59]	giv[56]|new[58]|giv[59]	_	_
6-33	1166-1174	examples	abstract[56]|abstract[58]|abstract[59]	giv[56]|new[58]|giv[59]	_	_
6-34	1175-1187	demonstrated	abstract[56]|abstract[58]|abstract[59]	giv[56]|new[58]|giv[59]	_	_
6-35	1188-1190	in	abstract[56]|abstract[58]|abstract[59]	giv[56]|new[58]|giv[59]	_	_
6-36	1191-1194	the	abstract[56]|abstract[58]|abstract[59]|time[60]	giv[56]|new[58]|giv[59]|new[60]	_	_
6-37	1195-1199	past	abstract[56]|abstract[58]|abstract[59]|time[60]	giv[56]|new[58]|giv[59]|new[60]	_	_
6-38	1200-1203	for	abstract[56]|abstract[58]|abstract[59]	giv[56]|new[58]|giv[59]	_	_
6-39	1204-1207	the	abstract[56]|abstract[58]|abstract[59]|abstract[62]	giv[56]|new[58]|giv[59]|giv[62]	coref	10-24[92_62]
6-40	1208-1213	batch	abstract[56]|abstract[58]|abstract[59]|abstract|abstract[62]	giv[56]|new[58]|giv[59]|giv|giv[62]	_	_
6-41	1214-1218	mode	abstract[56]|abstract[58]|abstract[59]|abstract[62]	giv[56]|new[58]|giv[59]|giv[62]	_	_
6-42	1219-1220	.	_	_	_	_

#Text=Recently , significant process in the biocatalytic reductive synthesis of alcohols starting from ketones , as well as syntheses by non-enzymatic means , have been reported .
7-1	1221-1229	Recently	_	_	_	_
7-2	1230-1231	,	_	_	_	_
7-3	1232-1243	significant	abstract[63]	new[63]	coref	14-7[119_63]
7-4	1244-1251	process	abstract[63]	new[63]	_	_
7-5	1252-1254	in	abstract[63]	new[63]	_	_
7-6	1255-1258	the	abstract[63]|event[64]	new[63]|new[64]	_	_
7-7	1259-1271	biocatalytic	abstract[63]|event[64]	new[63]|new[64]	_	_
7-8	1272-1281	reductive	abstract[63]|event[64]	new[63]|new[64]	_	_
7-9	1282-1291	synthesis	abstract[63]|event[64]	new[63]|new[64]	_	_
7-10	1292-1294	of	abstract[63]|event[64]	new[63]|new[64]	_	_
7-11	1295-1303	alcohols	abstract[63]|event[64]|substance[65]	new[63]|new[64]|new[65]	_	_
7-12	1304-1312	starting	abstract[63]|event[64]|substance[65]	new[63]|new[64]|new[65]	_	_
7-13	1313-1317	from	abstract[63]|event[64]|substance[65]	new[63]|new[64]|new[65]	_	_
7-14	1318-1325	ketones	abstract[63]|event[64]|substance[65]|substance	new[63]|new[64]|new[65]|new	_	_
7-15	1326-1327	,	abstract[63]	new[63]	_	_
7-16	1328-1330	as	abstract[63]	new[63]	_	_
7-17	1331-1335	well	abstract[63]	new[63]	_	_
7-18	1336-1338	as	abstract[63]	new[63]	_	_
7-19	1339-1348	syntheses	abstract[63]|abstract[67]	new[63]|new[67]	_	_
7-20	1349-1351	by	abstract[63]|abstract[67]	new[63]|new[67]	_	_
7-21	1352-1365	non-enzymatic	abstract[63]|abstract[67]|abstract[68]	new[63]|new[67]|new[68]	coref	13-3[113_68]
7-22	1366-1371	means	abstract[63]|abstract[67]|abstract[68]	new[63]|new[67]|new[68]	_	_
7-23	1372-1373	,	_	_	_	_
7-24	1374-1378	have	_	_	_	_
7-25	1379-1383	been	_	_	_	_
7-26	1384-1392	reported	_	_	_	_
7-27	1393-1394	.	_	_	_	_

#Text=In recent years , an increasing number of examples of biocatalysis in flow processes have been reported .
8-1	1395-1397	In	_	_	_	_
8-2	1398-1404	recent	time[69]	giv[69]	coref	19-7[152_69]
8-3	1405-1410	years	time[69]	giv[69]	_	_
8-4	1411-1412	,	_	_	_	_
8-5	1413-1415	an	abstract[70]	new[70]	_	_
8-6	1416-1426	increasing	abstract[70]	new[70]	_	_
8-7	1427-1433	number	abstract[70]	new[70]	_	_
8-8	1434-1436	of	abstract[70]	new[70]	_	_
8-9	1437-1445	examples	abstract[70]|abstract[71]	new[70]|giv[71]	_	_
8-10	1446-1448	of	abstract[70]|abstract[71]	new[70]|giv[71]	_	_
8-11	1449-1461	biocatalysis	abstract[70]|abstract[71]|abstract[72]	new[70]|giv[71]|new[72]	_	_
8-12	1462-1464	in	abstract[70]|abstract[71]|abstract[72]	new[70]|giv[71]|new[72]	_	_
8-13	1465-1469	flow	abstract[70]|abstract[71]|abstract[72]|abstract|abstract[74]	new[70]|giv[71]|new[72]|giv|giv[74]	coref|coref	9-23|9-23[83_74]
8-14	1470-1479	processes	abstract[70]|abstract[71]|abstract[72]|abstract[74]	new[70]|giv[71]|new[72]|giv[74]	_	_
8-15	1480-1484	have	_	_	_	_
8-16	1485-1489	been	_	_	_	_
8-17	1490-1498	reported	_	_	_	_
8-18	1499-1500	.	_	_	_	_

#Text=Although only being studied to a minor extent , some examples of ketone reductions with an alcohol dehydrogenase ( ADH ) in flow processes have been described .
9-1	1501-1509	Although	_	_	_	_
9-2	1510-1514	only	_	_	_	_
9-3	1515-1520	being	_	_	_	_
9-4	1521-1528	studied	_	_	_	_
9-5	1529-1531	to	_	_	_	_
9-6	1532-1533	a	abstract[75]	new[75]	_	_
9-7	1534-1539	minor	abstract[75]	new[75]	_	_
9-8	1540-1546	extent	abstract[75]	new[75]	_	_
9-9	1547-1548	,	_	_	_	_
9-10	1549-1553	some	abstract[76]	new[76]	_	_
9-11	1554-1562	examples	abstract[76]	new[76]	_	_
9-12	1563-1565	of	abstract[76]	new[76]	_	_
9-13	1566-1572	ketone	abstract[76]|substance|abstract[78]	new[76]|giv|new[78]	coref	10-21
9-14	1573-1583	reductions	abstract[76]|abstract[78]	new[76]|new[78]	_	_
9-15	1584-1588	with	abstract[76]|abstract[78]	new[76]|new[78]	_	_
9-16	1589-1591	an	abstract[76]|abstract[78]|abstract[80]	new[76]|new[78]|new[80]	appos	9-20[0_80]
9-17	1592-1599	alcohol	abstract[76]|abstract[78]|substance|abstract[80]	new[76]|new[78]|new|new[80]	_	_
9-18	1600-1613	dehydrogenase	abstract[76]|abstract[78]|abstract[80]	new[76]|new[78]|new[80]	_	_
9-19	1614-1615	(	abstract[76]|abstract[78]	new[76]|new[78]	_	_
9-20	1616-1619	ADH	abstract[76]|abstract[78]|abstract	new[76]|new[78]|giv	coref	10-40[97_0]
9-21	1620-1621	)	abstract[76]|abstract[78]	new[76]|new[78]	_	_
9-22	1622-1624	in	abstract[76]|abstract[78]	new[76]|new[78]	_	_
9-23	1625-1629	flow	abstract[76]|abstract[78]|abstract|abstract[83]	new[76]|new[78]|giv|giv[83]	coref|coref	11-16|15-2[124_83]
9-24	1630-1639	processes	abstract[76]|abstract[78]|abstract[83]	new[76]|new[78]|giv[83]	_	_
9-25	1640-1644	have	_	_	_	_
9-26	1645-1649	been	_	_	_	_
9-27	1650-1659	described	_	_	_	_
9-28	1660-1661	.	_	_	_	_

#Text=For example , Wandrey ’s and Liese ’s groups studied in detail the application of enzyme membrane reactors for enzymatic ketone reduction in a continuously running mode , and packed bed reactor setups were described by further groups using carrier-bound ADH from Lactobacillus brevis ( LB-ADH ) in combination with a mobile aqueous phase , or magnetic nanoparticle-bound ADH .
10-1	1662-1665	For	_	_	_	_
10-2	1666-1673	example	_	_	_	_
10-3	1674-1675	,	_	_	_	_
10-4	1676-1683	Wandrey	person[84]|person[86]	new[84]|new[86]	coref	10-37[96_86]
10-5	1684-1686	’s	person[84]|person[86]	new[84]|new[86]	_	_
10-6	1687-1690	and	person[86]	new[86]	_	_
10-7	1691-1696	Liese	person[85]|person[86]	new[85]|new[86]	_	_
10-8	1697-1699	’s	person[85]|person[86]	new[85]|new[86]	_	_
10-9	1700-1706	groups	person[86]	new[86]	_	_
10-10	1707-1714	studied	_	_	_	_
10-11	1715-1717	in	_	_	_	_
10-12	1718-1724	detail	_	_	_	_
10-13	1725-1728	the	abstract[87]	giv[87]	coref	28-8[220_87]
10-14	1729-1740	application	abstract[87]	giv[87]	_	_
10-15	1741-1743	of	abstract[87]	giv[87]	_	_
10-16	1744-1750	enzyme	abstract[87]|object[89]	giv[87]|new[89]	coref	15-5[126_89]
10-17	1751-1759	membrane	abstract[87]|substance|object[89]	giv[87]|new|new[89]	_	_
10-18	1760-1768	reactors	abstract[87]|object[89]	giv[87]|new[89]	_	_
10-19	1769-1772	for	abstract[87]|object[89]	giv[87]|new[89]	_	_
10-20	1773-1782	enzymatic	abstract[87]|object[89]|abstract[91]	giv[87]|new[89]|giv[91]	coref	13-9[0_91]
10-21	1783-1789	ketone	abstract[87]|object[89]|substance|abstract[91]	giv[87]|new[89]|giv|giv[91]	_	_
10-22	1790-1799	reduction	abstract[87]|object[89]|abstract[91]	giv[87]|new[89]|giv[91]	_	_
10-23	1800-1802	in	abstract[87]|object[89]|abstract[91]	giv[87]|new[89]|giv[91]	_	_
10-24	1803-1804	a	abstract[87]|object[89]|abstract[91]|abstract[92]	giv[87]|new[89]|giv[91]|giv[92]	_	_
10-25	1805-1817	continuously	abstract[87]|object[89]|abstract[91]|abstract[92]	giv[87]|new[89]|giv[91]|giv[92]	_	_
10-26	1818-1825	running	abstract[87]|object[89]|abstract[91]|abstract[92]	giv[87]|new[89]|giv[91]|giv[92]	_	_
10-27	1826-1830	mode	abstract[87]|object[89]|abstract[91]|abstract[92]	giv[87]|new[89]|giv[91]|giv[92]	_	_
10-28	1831-1832	,	_	_	_	_
10-29	1833-1836	and	_	_	_	_
10-30	1837-1843	packed	place[93]|abstract[95]	new[93]|new[95]	coref	15-5[125_93]
10-31	1844-1847	bed	place[93]|abstract[95]	new[93]|new[95]	_	_
10-32	1848-1855	reactor	object|abstract[95]	new|new[95]	coref	28-11[222_0]
10-33	1856-1862	setups	abstract[95]	new[95]	_	_
10-34	1863-1867	were	_	_	_	_
10-35	1868-1877	described	_	_	_	_
10-36	1878-1880	by	_	_	_	_
10-37	1881-1888	further	person[96]	giv[96]	_	_
10-38	1889-1895	groups	person[96]	giv[96]	_	_
10-39	1896-1901	using	person[96]	giv[96]	_	_
10-40	1902-1915	carrier-bound	person[96]|abstract[97]	giv[96]|giv[97]	coref	10-57[102_97]
10-41	1916-1919	ADH	person[96]|abstract[97]	giv[96]|giv[97]	_	_
10-42	1920-1924	from	person[96]|abstract[97]	giv[96]|giv[97]	_	_
10-43	1925-1938	Lactobacillus	person[96]|abstract[97]|abstract|abstract[99]	giv[96]|giv[97]|new|new[99]	coref	38-7[262_99]
10-44	1939-1945	brevis	person[96]|abstract[97]|abstract[99]	giv[96]|giv[97]|new[99]	_	_
10-45	1946-1947	(	person[96]	giv[96]	_	_
10-46	1948-1954	LB-ADH	person[96]|substance	giv[96]|new	coref	38-10
10-47	1955-1956	)	person[96]	giv[96]	_	_
10-48	1957-1959	in	person[96]	giv[96]	_	_
10-49	1960-1971	combination	person[96]	giv[96]	_	_
10-50	1972-1976	with	person[96]	giv[96]	_	_
10-51	1977-1978	a	person[96]|abstract[101]	giv[96]|new[101]	coref	28-29[0_101]
10-52	1979-1985	mobile	person[96]|abstract[101]	giv[96]|new[101]	_	_
10-53	1986-1993	aqueous	person[96]|abstract[101]	giv[96]|new[101]	_	_
10-54	1994-1999	phase	person[96]|abstract[101]	giv[96]|new[101]	_	_
10-55	2000-2001	,	person[96]	giv[96]	_	_
10-56	2002-2004	or	person[96]	giv[96]	_	_
10-57	2005-2013	magnetic	person[96]|abstract[102]	giv[96]|giv[102]	coref	11-12[0_102]
10-58	2014-2032	nanoparticle-bound	person[96]|abstract[102]	giv[96]|giv[102]	_	_
10-59	2033-2036	ADH	person[96]|abstract[102]	giv[96]|giv[102]	_	_
10-60	2037-2038	.	_	_	_	_

#Text=In addition , Buehler et al. investigated intensively the use of ADH in aqueous/organic segmented flow systems .
11-1	2039-2041	In	_	_	_	_
11-2	2042-2050	addition	_	_	_	_
11-3	2051-2052	,	_	_	_	_
11-4	2053-2060	Buehler	person	new	_	_
11-5	2061-2063	et	_	_	_	_
11-6	2064-2067	al.	_	_	_	_
11-7	2068-2080	investigated	_	_	_	_
11-8	2081-2092	intensively	_	_	_	_
11-9	2093-2096	the	abstract[104]	new[104]	ana	12-1[0_104]
11-10	2097-2100	use	abstract[104]	new[104]	_	_
11-11	2101-2103	of	abstract[104]	new[104]	_	_
11-12	2104-2107	ADH	abstract[104]|abstract	new[104]|giv	coref	26-5[205_0]
11-13	2108-2110	in	abstract[104]	new[104]	_	_
11-14	2111-2126	aqueous/organic	abstract[104]|abstract[107]	new[104]|new[107]	_	_
11-15	2127-2136	segmented	abstract[104]|abstract[107]	new[104]|new[107]	_	_
11-16	2137-2141	flow	abstract[104]|abstract|abstract[107]	new[104]|giv|new[107]	coref	14-17
11-17	2142-2149	systems	abstract[104]|abstract[107]	new[104]|new[107]	_	_
11-18	2150-2151	.	_	_	_	_

#Text=It was shown that emulsion formation could be eliminated , and enzymatic mass transfer-limited reactions can be enhanced .
12-1	2152-2154	It	abstract	giv	_	_
12-2	2155-2158	was	_	_	_	_
12-3	2159-2164	shown	_	_	_	_
12-4	2165-2169	that	_	_	_	_
12-5	2170-2178	emulsion	abstract|event[110]	new|new[110]	_	_
12-6	2179-2188	formation	event[110]	new[110]	_	_
12-7	2189-2194	could	_	_	_	_
12-8	2195-2197	be	_	_	_	_
12-9	2198-2208	eliminated	_	_	_	_
12-10	2209-2210	,	_	_	_	_
12-11	2211-2214	and	_	_	_	_
12-12	2215-2224	enzymatic	event[112]	giv[112]	_	_
12-13	2225-2229	mass	event[112]	giv[112]	_	_
12-14	2230-2246	transfer-limited	event|event[112]	new|giv[112]	_	_
12-15	2247-2256	reactions	event[112]	giv[112]	_	_
12-16	2257-2260	can	_	_	_	_
12-17	2261-2263	be	_	_	_	_
12-18	2264-2272	enhanced	_	_	_	_
12-19	2273-2274	.	_	_	_	_

#Text=Furthermore , different means of stabilization of this reaction system were investigated .
13-1	2275-2286	Furthermore	_	_	_	_
13-2	2287-2288	,	_	_	_	_
13-3	2289-2298	different	abstract[113]	giv[113]	_	_
13-4	2299-2304	means	abstract[113]	giv[113]	_	_
13-5	2305-2307	of	abstract[113]	giv[113]	_	_
13-6	2308-2321	stabilization	abstract[113]|abstract[114]	giv[113]|new[114]	_	_
13-7	2322-2324	of	abstract[113]|abstract[114]	giv[113]|new[114]	_	_
13-8	2325-2329	this	abstract[113]|abstract[114]|abstract[116]	giv[113]|new[114]|new[116]	_	_
13-9	2330-2338	reaction	abstract[113]|abstract[114]|abstract|abstract[116]	giv[113]|new[114]|giv|new[116]	coref	16-13
13-10	2339-2345	system	abstract[113]|abstract[114]|abstract[116]	giv[113]|new[114]|new[116]	_	_
13-11	2346-2350	were	_	_	_	_
13-12	2351-2363	investigated	_	_	_	_
13-13	2364-2365	.	_	_	_	_

#Text=Very recently , our group published an improved downstream process by means of such a segmented flow process , illustrated using two different ADHs and substrates .
14-1	2366-2370	Very	_	_	_	_
14-2	2371-2379	recently	_	_	_	_
14-3	2380-2381	,	_	_	_	_
14-4	2382-2385	our	person|person[118]	acc|new[118]	_	_
14-5	2386-2391	group	person[118]	new[118]	_	_
14-6	2392-2401	published	_	_	_	_
14-7	2402-2404	an	abstract[119]	giv[119]	coref	14-14[121_119]
14-8	2405-2413	improved	abstract[119]	giv[119]	_	_
14-9	2414-2424	downstream	abstract[119]	giv[119]	_	_
14-10	2425-2432	process	abstract[119]	giv[119]	_	_
14-11	2433-2435	by	_	_	_	_
14-12	2436-2441	means	_	_	_	_
14-13	2442-2444	of	_	_	_	_
14-14	2445-2449	such	abstract[121]	giv[121]	coref	18-11[146_121]
14-15	2450-2451	a	abstract[121]	giv[121]	_	_
14-16	2452-2461	segmented	abstract[121]	giv[121]	_	_
14-17	2462-2466	flow	abstract|abstract[121]	giv|giv[121]	_	_
14-18	2467-2474	process	abstract[121]	giv[121]	_	_
14-19	2475-2476	,	abstract[121]	giv[121]	_	_
14-20	2477-2488	illustrated	abstract[121]	giv[121]	_	_
14-21	2489-2494	using	_	_	_	_
14-22	2495-2498	two	abstract[122]	new[122]	coref	25-11[0_122]
14-23	2499-2508	different	abstract[122]	new[122]	_	_
14-24	2509-2513	ADHs	abstract[122]	new[122]	_	_
14-25	2514-2517	and	_	_	_	_
14-26	2518-2528	substrates	object	new	_	_
14-27	2529-2530	.	_	_	_	_

#Text=In continuous processes using packed bed reactors ( PBR ) , catalyst immobilization is a prerequisite .
15-1	2531-2533	In	_	_	_	_
15-2	2534-2544	continuous	abstract[124]	giv[124]	coref	16-3[131_124]
15-3	2545-2554	processes	abstract[124]	giv[124]	_	_
15-4	2555-2560	using	abstract[124]	giv[124]	_	_
15-5	2561-2567	packed	abstract[124]|place[125]|object[126]	giv[124]|giv[125]|giv[126]	coref	28-12[221_125]
15-6	2568-2571	bed	abstract[124]|place[125]|object[126]	giv[124]|giv[125]|giv[126]	_	_
15-7	2572-2580	reactors	abstract[124]|object[126]	giv[124]|giv[126]	_	_
15-8	2581-2582	(	_	_	_	_
15-9	2583-2586	PBR	abstract	new	_	_
15-10	2587-2588	)	_	_	_	_
15-11	2589-2590	,	_	_	_	_
15-12	2591-2599	catalyst	substance|object[129]	new|new[129]	coref|coref	15-15[130_129]|16-16[136_0]
15-13	2600-2614	immobilization	object[129]	new[129]	_	_
15-14	2615-2617	is	_	_	_	_
15-15	2618-2619	a	object[130]	giv[130]	coref	16-7[0_130]
15-16	2620-2632	prerequisite	object[130]	giv[130]	_	_
15-17	2633-2634	.	_	_	_	_

#Text=Also , downstream processes benefit from immobilization , as separation of the reaction mixture from the catalyst is easier , and the catalyst reusability is improved .
16-1	2635-2639	Also	_	_	_	_
16-2	2640-2641	,	_	_	_	_
16-3	2642-2652	downstream	abstract[131]	giv[131]	_	_
16-4	2653-2662	processes	abstract[131]	giv[131]	_	_
16-5	2663-2670	benefit	_	_	_	_
16-6	2671-2675	from	_	_	_	_
16-7	2676-2690	immobilization	object	giv	coref	18-12
16-8	2691-2692	,	_	_	_	_
16-9	2693-2695	as	_	_	_	_
16-10	2696-2706	separation	abstract[133]	new[133]	_	_
16-11	2707-2709	of	abstract[133]	new[133]	_	_
16-12	2710-2713	the	abstract[133]|substance[135]	new[133]|new[135]	_	_
16-13	2714-2722	reaction	abstract[133]|abstract|substance[135]	new[133]|giv|new[135]	_	_
16-14	2723-2730	mixture	abstract[133]|substance[135]	new[133]|new[135]	_	_
16-15	2731-2735	from	abstract[133]|substance[135]	new[133]|new[135]	_	_
16-16	2736-2739	the	abstract[133]|substance[135]|substance[136]	new[133]|new[135]|giv[136]	coref	16-23[0_136]
16-17	2740-2748	catalyst	abstract[133]|substance[135]|substance[136]	new[133]|new[135]|giv[136]	_	_
16-18	2749-2751	is	_	_	_	_
16-19	2752-2758	easier	_	_	_	_
16-20	2759-2760	,	_	_	_	_
16-21	2761-2764	and	_	_	_	_
16-22	2765-2768	the	abstract[138]	new[138]	ana	17-3[0_138]
16-23	2769-2777	catalyst	substance|abstract[138]	giv|new[138]	coref	17-13[142_0]
16-24	2778-2789	reusability	abstract[138]	new[138]	_	_
16-25	2790-2792	is	_	_	_	_
16-26	2793-2801	improved	_	_	_	_
16-27	2802-2803	.	_	_	_	_

#Text=Moreover , both , operational , as well as storage stability of the catalyst can potentially be significantly increased .
17-1	2804-2812	Moreover	_	_	_	_
17-2	2813-2814	,	_	_	_	_
17-3	2815-2819	both	abstract	giv	coref	27-21[219_0]
17-4	2820-2821	,	_	_	_	_
17-5	2822-2833	operational	abstract[141]	new[141]	_	_
17-6	2834-2835	,	abstract[141]	new[141]	_	_
17-7	2836-2838	as	abstract[141]	new[141]	_	_
17-8	2839-2843	well	abstract[141]	new[141]	_	_
17-9	2844-2846	as	abstract[141]	new[141]	_	_
17-10	2847-2854	storage	place|abstract[141]	new|new[141]	_	_
17-11	2855-2864	stability	abstract[141]	new[141]	_	_
17-12	2865-2867	of	abstract[141]	new[141]	_	_
17-13	2868-2871	the	abstract[141]|substance[142]	new[141]|giv[142]	coref	18-23[149_142]
17-14	2872-2880	catalyst	abstract[141]|substance[142]	new[141]|giv[142]	_	_
17-15	2881-2884	can	_	_	_	_
17-16	2885-2896	potentially	_	_	_	_
17-17	2897-2899	be	_	_	_	_
17-18	2900-2913	significantly	_	_	_	_
17-19	2914-2923	increased	_	_	_	_
17-20	2924-2925	.	_	_	_	_

#Text=However , often a significant loss of enzymatic activity during the immobilization process represents a drawback , and the reproducible production of immobilized catalyst may be a further challenge .
18-1	2926-2933	However	_	_	_	_
18-2	2934-2935	,	_	_	_	_
18-3	2936-2941	often	_	_	_	_
18-4	2942-2943	a	event[143]	new[143]	coref	26-17[209_143]
18-5	2944-2955	significant	event[143]	new[143]	_	_
18-6	2956-2960	loss	event[143]	new[143]	_	_
18-7	2961-2963	of	event[143]	new[143]	_	_
18-8	2964-2973	enzymatic	event[143]|abstract[144]	new[143]|new[144]	coref	26-21[0_144]
18-9	2974-2982	activity	event[143]|abstract[144]	new[143]|new[144]	_	_
18-10	2983-2989	during	event[143]	new[143]	_	_
18-11	2990-2993	the	event[143]|abstract[146]	new[143]|giv[146]	_	_
18-12	2994-3008	immobilization	event[143]|object|abstract[146]	new[143]|giv|giv[146]	coref	20-9[173_0]
18-13	3009-3016	process	event[143]|abstract[146]	new[143]|giv[146]	_	_
18-14	3017-3027	represents	_	_	_	_
18-15	3028-3029	a	abstract[147]	new[147]	_	_
18-16	3030-3038	drawback	abstract[147]	new[147]	_	_
18-17	3039-3040	,	_	_	_	_
18-18	3041-3044	and	_	_	_	_
18-19	3045-3048	the	event[148]	new[148]	coref	18-27[150_148]
18-20	3049-3061	reproducible	event[148]	new[148]	_	_
18-21	3062-3072	production	event[148]	new[148]	_	_
18-22	3073-3075	of	event[148]	new[148]	_	_
18-23	3076-3087	immobilized	event[148]|substance[149]	new[148]|giv[149]	coref	27-23[0_149]
18-24	3088-3096	catalyst	event[148]|substance[149]	new[148]|giv[149]	_	_
18-25	3097-3100	may	_	_	_	_
18-26	3101-3103	be	_	_	_	_
18-27	3104-3105	a	event[150]	giv[150]	_	_
18-28	3106-3113	further	event[150]	giv[150]	_	_
18-29	3114-3123	challenge	event[150]	giv[150]	_	_
18-30	3124-3125	.	_	_	_	_

#Text=Numerous techniques have been developed over the past years , which can be classified in the following three major methods : ( a ) binding to a solid support ( carrier ) , ( b ) entrapment ( encapsulation ) in polymer networks , or ( c ) cross-linking in the form of cross-linked enzyme aggregates ( CLEAs ) or cross-linked enzyme crystals ( CLECs ) .
19-1	3126-3134	Numerous	abstract[151]	new[151]	_	_
19-2	3135-3145	techniques	abstract[151]	new[151]	_	_
19-3	3146-3150	have	_	_	_	_
19-4	3151-3155	been	_	_	_	_
19-5	3156-3165	developed	_	_	_	_
19-6	3166-3170	over	_	_	_	_
19-7	3171-3174	the	time[152]	giv[152]	_	_
19-8	3175-3179	past	time[152]	giv[152]	_	_
19-9	3180-3185	years	time[152]	giv[152]	_	_
19-10	3186-3187	,	time[152]	giv[152]	_	_
19-11	3188-3193	which	time[152]	giv[152]	_	_
19-12	3194-3197	can	time[152]	giv[152]	_	_
19-13	3198-3200	be	time[152]	giv[152]	_	_
19-14	3201-3211	classified	time[152]	giv[152]	_	_
19-15	3212-3214	in	time[152]	giv[152]	_	_
19-16	3215-3218	the	time[152]|abstract[153]	giv[152]|new[153]	appos	19-25[155_153]
19-17	3219-3228	following	time[152]|abstract[153]	giv[152]|new[153]	_	_
19-18	3229-3234	three	time[152]|abstract[153]	giv[152]|new[153]	_	_
19-19	3235-3240	major	time[152]|abstract[153]	giv[152]|new[153]	_	_
19-20	3241-3248	methods	time[152]|abstract[153]	giv[152]|new[153]	_	_
19-21	3249-3250	:	time[152]|abstract[153]	giv[152]|new[153]	_	_
19-22	3251-3252	(	time[152]|abstract[153]	giv[152]|new[153]	_	_
19-23	3253-3254	a	time[152]|abstract[153]	giv[152]|new[153]	_	_
19-24	3255-3256	)	time[152]|abstract[153]	giv[152]|new[153]	_	_
19-25	3257-3264	binding	object|abstract[155]	new|giv[155]	appos	19-37[0_155]
19-26	3265-3267	to	abstract[155]	giv[155]	_	_
19-27	3268-3269	a	abstract[155]|object[156]	giv[155]|new[156]	coref	24-22[196_156]
19-28	3270-3275	solid	abstract[155]|object[156]	giv[155]|new[156]	_	_
19-29	3276-3283	support	abstract[155]|object[156]	giv[155]|new[156]	_	_
19-30	3284-3285	(	abstract[155]	giv[155]	_	_
19-31	3286-3293	carrier	abstract[155]|organization	giv[155]|new	_	_
19-32	3294-3295	)	abstract[155]	giv[155]	_	_
19-33	3296-3297	,	abstract[155]	giv[155]	_	_
19-34	3298-3299	(	abstract[155]	giv[155]	_	_
19-35	3300-3301	b	abstract[155]	giv[155]	_	_
19-36	3302-3303	)	abstract[155]	giv[155]	_	_
19-37	3304-3314	entrapment	abstract[155]|abstract	giv[155]|giv	appos	19-39
19-38	3315-3316	(	abstract[155]	giv[155]	_	_
19-39	3317-3330	encapsulation	abstract[155]|abstract	giv[155]|giv	appos	19-49
19-40	3331-3332	)	abstract[155]	giv[155]	_	_
19-41	3333-3335	in	abstract[155]	giv[155]	_	_
19-42	3336-3343	polymer	abstract[155]|substance|abstract[161]	giv[155]|new|new[161]	coref|coref	21-12|21-12[179_161]
19-43	3344-3352	networks	abstract[155]|abstract[161]	giv[155]|new[161]	_	_
19-44	3353-3354	,	abstract[155]	giv[155]	_	_
19-45	3355-3357	or	abstract[155]	giv[155]	_	_
19-46	3358-3359	(	abstract[155]	giv[155]	_	_
19-47	3360-3361	c	abstract[155]	giv[155]	_	_
19-48	3362-3363	)	abstract[155]	giv[155]	_	_
19-49	3364-3377	cross-linking	abstract[155]|abstract	giv[155]|giv	_	_
19-50	3378-3380	in	_	_	_	_
19-51	3381-3384	the	abstract[163]	new[163]	coref	25-21[203_163]
19-52	3385-3389	form	abstract[163]	new[163]	_	_
19-53	3390-3392	of	abstract[163]	new[163]	_	_
19-54	3393-3405	cross-linked	abstract[163]|abstract[165]	new[163]|new[165]	appos	19-58[0_165]
19-55	3406-3412	enzyme	abstract[163]|substance|abstract[165]	new[163]|new|new[165]	coref	19-61[167_0]
19-56	3413-3423	aggregates	abstract[163]|abstract[165]	new[163]|new[165]	_	_
19-57	3424-3425	(	_	_	_	_
19-58	3426-3431	CLEAs	abstract	giv	_	_
19-59	3432-3433	)	_	_	_	_
19-60	3434-3436	or	_	_	_	_
19-61	3437-3449	cross-linked	substance[167]|object[168]	giv[167]|new[168]	coref	20-9[0_167]
19-62	3450-3456	enzyme	substance[167]|object[168]	giv[167]|new[168]	_	_
19-63	3457-3465	crystals	object[168]	new[168]	_	_
19-64	3466-3467	(	_	_	_	_
19-65	3468-3473	CLECs	abstract	new	_	_
19-66	3474-3475	)	_	_	_	_
19-67	3476-3477	.	_	_	_	_

#Text=Recently , much progress in the field of enzyme immobilization has been made .
20-1	3478-3486	Recently	_	_	_	_
20-2	3487-3488	,	_	_	_	_
20-3	3489-3493	much	abstract[170]	new[170]	_	_
20-4	3494-3502	progress	abstract[170]	new[170]	_	_
20-5	3503-3505	in	abstract[170]	new[170]	_	_
20-6	3506-3509	the	abstract[170]|abstract[171]	new[170]|new[171]	_	_
20-7	3510-3515	field	abstract[170]|abstract[171]	new[170]|new[171]	_	_
20-8	3516-3518	of	abstract[170]|abstract[171]	new[170]|new[171]	_	_
20-9	3519-3525	enzyme	abstract[170]|abstract[171]|substance|object[173]	new[170]|new[171]|giv|giv[173]	coref|coref	24-5[190_0]|27-13[0_173]
20-10	3526-3540	immobilization	abstract[170]|abstract[171]|object[173]	new[170]|new[171]|giv[173]	_	_
20-11	3541-3544	has	_	_	_	_
20-12	3545-3549	been	_	_	_	_
20-13	3550-3554	made	_	_	_	_
20-14	3555-3556	.	_	_	_	_

#Text=In this work , the option of entrapment of enzymes in polymer networks has been chosen .
21-1	3557-3559	In	_	_	_	_
21-2	3560-3564	this	abstract[174]	new[174]	_	_
21-3	3565-3569	work	abstract[174]	new[174]	_	_
21-4	3570-3571	,	_	_	_	_
21-5	3572-3575	the	abstract[175]	new[175]	_	_
21-6	3576-3582	option	abstract[175]	new[175]	_	_
21-7	3583-3585	of	abstract[175]	new[175]	_	_
21-8	3586-3596	entrapment	abstract[175]|event[176]	new[175]|new[176]	_	_
21-9	3597-3599	of	abstract[175]|event[176]	new[175]|new[176]	_	_
21-10	3600-3607	enzymes	abstract[175]|event[176]|substance	new[175]|new[176]|new	_	_
21-11	3608-3610	in	abstract[175]|event[176]	new[175]|new[176]	_	_
21-12	3611-3618	polymer	abstract[175]|event[176]|substance|abstract[179]	new[175]|new[176]|giv|giv[179]	coref	29-1[229_0]
21-13	3619-3627	networks	abstract[175]|event[176]|abstract[179]	new[175]|new[176]|giv[179]	_	_
21-14	3628-3631	has	_	_	_	_
21-15	3632-3636	been	_	_	_	_
21-16	3637-3643	chosen	_	_	_	_
21-17	3644-3645	.	_	_	_	_

#Text=Often for this purpose , organic polymers containing cavities , sol-gel-processed particles , or membranes are used .
22-1	3646-3651	Often	_	_	_	_
22-2	3652-3655	for	_	_	_	_
22-3	3656-3660	this	abstract[180]	new[180]	_	_
22-4	3661-3668	purpose	abstract[180]	new[180]	_	_
22-5	3669-3670	,	_	_	_	_
22-6	3671-3678	organic	substance[181]	new[181]	coref	23-8[187_181]
22-7	3679-3687	polymers	substance[181]	new[181]	_	_
22-8	3688-3698	containing	substance[181]	new[181]	_	_
22-9	3699-3707	cavities	substance[181]|substance	new[181]|new	_	_
22-10	3708-3709	,	substance[181]	new[181]	_	_
22-11	3710-3727	sol-gel-processed	substance[181]|object[183]	new[181]|new[183]	_	_
22-12	3728-3737	particles	substance[181]|object[183]	new[181]|new[183]	_	_
22-13	3738-3739	,	substance[181]	new[181]	_	_
22-14	3740-3742	or	substance[181]	new[181]	_	_
22-15	3743-3752	membranes	substance[181]|object	new[181]|new	_	_
22-16	3753-3756	are	_	_	_	_
22-17	3757-3761	used	_	_	_	_
22-18	3762-3763	.	_	_	_	_

#Text=A special case is the use of superabsorbent polymers to immobilize the entire aqueous phase. .
23-1	3764-3765	A	event[185]	new[185]	coref	23-5[186_185]
23-2	3766-3773	special	event[185]	new[185]	_	_
23-3	3774-3778	case	event[185]	new[185]	_	_
23-4	3779-3781	is	_	_	_	_
23-5	3782-3785	the	event[186]	giv[186]	coref	24-2[189_186]
23-6	3786-3789	use	event[186]	giv[186]	_	_
23-7	3790-3792	of	event[186]	giv[186]	_	_
23-8	3793-3807	superabsorbent	event[186]|substance[187]	giv[186]|giv[187]	_	_
23-9	3808-3816	polymers	event[186]|substance[187]	giv[186]|giv[187]	_	_
23-10	3817-3819	to	event[186]	giv[186]	_	_
23-11	3820-3830	immobilize	event[186]	giv[186]	_	_
23-12	3831-3834	the	event[186]|abstract[188]	giv[186]|new[188]	_	_
23-13	3835-3841	entire	event[186]|abstract[188]	giv[186]|new[188]	_	_
23-14	3842-3849	aqueous	event[186]|abstract[188]	giv[186]|new[188]	_	_
23-15	3850-3856	phase.	event[186]|abstract[188]	giv[186]|new[188]	_	_
23-16	3857-3858	.	_	_	_	_

#Text=In this case , the enzyme is immobilized in its native aqueous environment , whereby undesired interactions of protein moieties with the support can be prevented .
24-1	3859-3861	In	_	_	_	_
24-2	3862-3866	this	event[189]	giv[189]	ana	24-10[0_189]
24-3	3867-3871	case	event[189]	giv[189]	_	_
24-4	3872-3873	,	_	_	_	_
24-5	3874-3877	the	substance[190]	giv[190]	coref	35-6[0_190]
24-6	3878-3884	enzyme	substance[190]	giv[190]	_	_
24-7	3885-3887	is	_	_	_	_
24-8	3888-3899	immobilized	_	_	_	_
24-9	3900-3902	in	_	_	_	_
24-10	3903-3906	its	event|place[192]	giv|new[192]	_	_
24-11	3907-3913	native	place[192]	new[192]	_	_
24-12	3914-3921	aqueous	place[192]	new[192]	_	_
24-13	3922-3933	environment	place[192]	new[192]	_	_
24-14	3934-3935	,	_	_	_	_
24-15	3936-3943	whereby	_	_	_	_
24-16	3944-3953	undesired	event[193]	new[193]	_	_
24-17	3954-3966	interactions	event[193]	new[193]	_	_
24-18	3967-3969	of	event[193]	new[193]	_	_
24-19	3970-3977	protein	event[193]|substance|object[195]	new[193]|new|new[195]	coref|coref	30-21[238_195]|30-30[242_0]
24-20	3978-3986	moieties	event[193]|object[195]	new[193]|new[195]	_	_
24-21	3987-3991	with	event[193]	new[193]	_	_
24-22	3992-3995	the	event[193]|object[196]	new[193]|giv[196]	_	_
24-23	3996-4003	support	event[193]|object[196]	new[193]|giv[196]	_	_
24-24	4004-4007	can	_	_	_	_
24-25	4008-4010	be	_	_	_	_
24-26	4011-4020	prevented	_	_	_	_
24-27	4021-4022	.	_	_	_	_

#Text=Recently , Gröger et al. applied a method of immobilizing ADHs with superabsorber efficiently for the synthesis of diols in enantiomerically pure form .
25-1	4023-4031	Recently	_	_	_	_
25-2	4032-4033	,	_	_	_	_
25-3	4034-4040	Gröger	person	new	_	_
25-4	4041-4043	et	_	_	_	_
25-5	4044-4047	al.	_	_	_	_
25-6	4048-4055	applied	_	_	_	_
25-7	4056-4057	a	abstract[198]	new[198]	coref	27-3[212_198]
25-8	4058-4064	method	abstract[198]	new[198]	_	_
25-9	4065-4067	of	abstract[198]	new[198]	_	_
25-10	4068-4080	immobilizing	abstract[198]	new[198]	_	_
25-11	4081-4085	ADHs	abstract[198]|abstract	new[198]|giv	_	_
25-12	4086-4090	with	abstract[198]	new[198]	_	_
25-13	4091-4104	superabsorber	abstract[198]|object	new[198]|new	coref	33-10
25-14	4105-4116	efficiently	abstract[198]	new[198]	_	_
25-15	4117-4120	for	_	_	_	_
25-16	4121-4124	the	abstract[201]	new[201]	_	_
25-17	4125-4134	synthesis	abstract[201]	new[201]	_	_
25-18	4135-4137	of	abstract[201]	new[201]	_	_
25-19	4138-4143	diols	abstract[201]|substance[202]	new[201]|new[202]	_	_
25-20	4144-4146	in	abstract[201]|substance[202]	new[201]|new[202]	_	_
25-21	4147-4163	enantiomerically	abstract[201]|substance[202]|abstract[203]	new[201]|new[202]|giv[203]	_	_
25-22	4164-4168	pure	abstract[201]|substance[202]|abstract[203]	new[201]|new[202]|giv[203]	_	_
25-23	4169-4173	form	abstract[201]|substance[202]|abstract[203]	new[201]|new[202]|giv[203]	_	_
25-24	4174-4175	.	_	_	_	_

#Text=In this example , the immobilized ADH from Rhodococcus sp. was used in organic solvents without a major loss in activity .
26-1	4176-4178	In	_	_	_	_
26-2	4179-4183	this	abstract[204]	new[204]	_	_
26-3	4184-4191	example	abstract[204]	new[204]	_	_
26-4	4192-4193	,	_	_	_	_
26-5	4194-4197	the	abstract[205]	giv[205]	coref	38-1[261_205]
26-6	4198-4209	immobilized	abstract[205]	giv[205]	_	_
26-7	4210-4213	ADH	abstract[205]	giv[205]	_	_
26-8	4214-4218	from	abstract[205]	giv[205]	_	_
26-9	4219-4230	Rhodococcus	abstract[205]|abstract	giv[205]|new	_	_
26-10	4231-4234	sp.	abstract[205]|plant	giv[205]|new	_	_
26-11	4235-4238	was	_	_	_	_
26-12	4239-4243	used	_	_	_	_
26-13	4244-4246	in	_	_	_	_
26-14	4247-4254	organic	substance[208]	new[208]	coref	40-7[275_208]
26-15	4255-4263	solvents	substance[208]	new[208]	_	_
26-16	4264-4271	without	_	_	_	_
26-17	4272-4273	a	event[209]	giv[209]	_	_
26-18	4274-4279	major	event[209]	giv[209]	_	_
26-19	4280-4284	loss	event[209]	giv[209]	_	_
26-20	4285-4287	in	event[209]	giv[209]	_	_
26-21	4288-4296	activity	event[209]|abstract	giv[209]|giv	_	_
26-22	4297-4298	.	_	_	_	_

#Text=Advantages of this method is the low cost , the very fast immobilization procedure ( <30 min ) , and the excellent catalyst reusability .
27-1	4299-4309	Advantages	abstract[211]	new[211]	coref	27-6[213_211]
27-2	4310-4312	of	abstract[211]	new[211]	_	_
27-3	4313-4317	this	abstract[211]|abstract[212]	new[211]|giv[212]	_	_
27-4	4318-4324	method	abstract[211]|abstract[212]	new[211]|giv[212]	_	_
27-5	4325-4327	is	_	_	_	_
27-6	4328-4331	the	abstract[213]|abstract[214]	giv[213]|giv[214]	coref	27-6[214_213]
27-7	4332-4335	low	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
27-8	4336-4340	cost	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
27-9	4341-4342	,	abstract[214]	giv[214]	_	_
27-10	4343-4346	the	abstract[214]|event[216]	giv[214]|new[216]	_	_
27-11	4347-4351	very	abstract[214]|event[216]	giv[214]|new[216]	_	_
27-12	4352-4356	fast	abstract[214]|event[216]	giv[214]|new[216]	_	_
27-13	4357-4371	immobilization	abstract[214]|object|event[216]	giv[214]|giv|new[216]	_	_
27-14	4372-4381	procedure	abstract[214]|event[216]	giv[214]|new[216]	_	_
27-15	4382-4383	(	abstract[214]	giv[214]	_	_
27-16	4384-4387	<30	abstract[214]|time[217]	giv[214]|new[217]	_	_
27-17	4388-4391	min	abstract[214]|time[217]	giv[214]|new[217]	_	_
27-18	4392-4393	)	abstract[214]	giv[214]	_	_
27-19	4394-4395	,	abstract[214]	giv[214]	_	_
27-20	4396-4399	and	abstract[214]	giv[214]	_	_
27-21	4400-4403	the	abstract[214]|abstract[219]	giv[214]|giv[219]	_	_
27-22	4404-4413	excellent	abstract[214]|abstract[219]	giv[214]|giv[219]	_	_
27-23	4414-4422	catalyst	abstract[214]|substance|abstract[219]	giv[214]|giv|giv[219]	coref	38-17[264_0]
27-24	4423-4434	reusability	abstract[214]|abstract[219]	giv[214]|giv[219]	_	_
27-25	4435-4436	.	_	_	_	_

#Text=Challenging , in particular with respect to an application in a fixed bed reactor , might be the gel-like consistency of the hydrogel and mass transfer limitations through phase interfaces in general .
28-1	4437-4448	Challenging	abstract[223]	new[223]	_	_
28-2	4449-4450	,	abstract[223]	new[223]	_	_
28-3	4451-4453	in	abstract[223]	new[223]	_	_
28-4	4454-4464	particular	abstract[223]	new[223]	_	_
28-5	4465-4469	with	abstract[223]	new[223]	_	_
28-6	4470-4477	respect	abstract[223]	new[223]	_	_
28-7	4478-4480	to	abstract[223]	new[223]	_	_
28-8	4481-4483	an	abstract[220]|abstract[223]	giv[220]|new[223]	_	_
28-9	4484-4495	application	abstract[220]|abstract[223]	giv[220]|new[223]	_	_
28-10	4496-4498	in	abstract[220]|abstract[223]	giv[220]|new[223]	_	_
28-11	4499-4500	a	abstract[220]|object[222]|abstract[223]	giv[220]|giv[222]|new[223]	_	_
28-12	4501-4506	fixed	abstract[220]|place[221]|object[222]|abstract[223]	giv[220]|giv[221]|giv[222]|new[223]	_	_
28-13	4507-4510	bed	abstract[220]|place[221]|object[222]|abstract[223]	giv[220]|giv[221]|giv[222]|new[223]	_	_
28-14	4511-4518	reactor	abstract[220]|object[222]|abstract[223]	giv[220]|giv[222]|new[223]	_	_
28-15	4519-4520	,	abstract[223]	new[223]	_	_
28-16	4521-4526	might	abstract[223]	new[223]	_	_
28-17	4527-4529	be	abstract[223]	new[223]	_	_
28-18	4530-4533	the	abstract[223]	new[223]	_	_
28-19	4534-4542	gel-like	abstract[223]	new[223]	_	_
28-20	4543-4554	consistency	abstract[223]	new[223]	_	_
28-21	4555-4557	of	abstract[223]	new[223]	_	_
28-22	4558-4561	the	abstract[223]|substance[224]	new[223]|new[224]	_	_
28-23	4562-4570	hydrogel	abstract[223]|substance[224]	new[223]|new[224]	_	_
28-24	4571-4574	and	_	_	_	_
28-25	4575-4579	mass	abstract[226]	new[226]	_	_
28-26	4580-4588	transfer	abstract|abstract[226]	new|new[226]	_	_
28-27	4589-4600	limitations	abstract[226]	new[226]	_	_
28-28	4601-4608	through	abstract[226]	new[226]	_	_
28-29	4609-4614	phase	abstract[226]|abstract|abstract[228]	new[226]|giv|new[228]	_	_
28-30	4615-4625	interfaces	abstract[226]|abstract[228]	new[226]|new[228]	_	_
28-31	4626-4628	in	abstract[226]	new[226]	_	_
28-32	4629-4636	general	abstract[226]	new[226]	_	_
28-33	4637-4638	.	_	_	_	_

#Text=The absorbent polymer consists of cross-linked polyacrylic acid , which was partially neutralized .
29-1	4639-4642	The	substance[229]	giv[229]	coref	30-7[0_229]
29-2	4643-4652	absorbent	substance[229]	giv[229]	_	_
29-3	4653-4660	polymer	substance[229]	giv[229]	_	_
29-4	4661-4669	consists	_	_	_	_
29-5	4670-4672	of	_	_	_	_
29-6	4673-4685	cross-linked	substance[231]	new[231]	coref	30-22[0_231]
29-7	4686-4697	polyacrylic	person|substance[231]	new|new[231]	_	_
29-8	4698-4702	acid	substance[231]	new[231]	_	_
29-9	4703-4704	,	substance[231]	new[231]	_	_
29-10	4705-4710	which	substance[231]	new[231]	_	_
29-11	4711-4714	was	substance[231]	new[231]	_	_
29-12	4715-4724	partially	substance[231]	new[231]	_	_
29-13	4725-4736	neutralized	substance[231]	new[231]	_	_
29-14	4737-4738	.	_	_	_	_

#Text=Proteins can be embedded in this polymer matrix and can be bound , for example , by ionic interactions of its acid moieties to ionic amino acid residues of the protein ( see
30-1	4739-4747	Proteins	substance	new	_	_
30-2	4748-4751	can	_	_	_	_
30-3	4752-4754	be	_	_	_	_
30-4	4755-4763	embedded	_	_	_	_
30-5	4764-4766	in	_	_	_	_
30-6	4767-4771	this	object[234]	new[234]	ana	30-21[0_234]
30-7	4772-4779	polymer	substance|object[234]	giv|new[234]	_	_
30-8	4780-4786	matrix	object[234]	new[234]	_	_
30-9	4787-4790	and	_	_	_	_
30-10	4791-4794	can	_	_	_	_
30-11	4795-4797	be	_	_	_	_
30-12	4798-4803	bound	_	_	_	_
30-13	4804-4805	,	_	_	_	_
30-14	4806-4809	for	_	_	_	_
30-15	4810-4817	example	_	_	_	_
30-16	4818-4819	,	_	_	_	_
30-17	4820-4822	by	_	_	_	_
30-18	4823-4828	ionic	event[235]	new[235]	_	_
30-19	4829-4841	interactions	event[235]	new[235]	_	_
30-20	4842-4844	of	event[235]	new[235]	_	_
30-21	4845-4848	its	event[235]|object|object[238]	new[235]|giv|giv[238]	_	_
30-22	4849-4853	acid	event[235]|substance|object[238]	new[235]|giv|giv[238]	coref	30-26[240_0]
30-23	4854-4862	moieties	event[235]|object[238]	new[235]|giv[238]	_	_
30-24	4863-4865	to	event[235]	new[235]	_	_
30-25	4866-4871	ionic	event[235]|object[241]	new[235]|new[241]	coref	33-6[247_241]
30-26	4872-4877	amino	event[235]|object|substance[240]|object[241]	new[235]|new|giv[240]|new[241]	_	_
30-27	4878-4882	acid	event[235]|substance[240]|object[241]	new[235]|giv[240]|new[241]	_	_
30-28	4883-4891	residues	event[235]|object[241]	new[235]|new[241]	_	_
30-29	4892-4894	of	event[235]|object[241]	new[235]|new[241]	_	_
30-30	4895-4898	the	event[235]|object[241]|substance[242]	new[235]|new[241]|giv[242]	coref	33-7[0_242]
30-31	4899-4906	protein	event[235]|object[241]|substance[242]	new[235]|new[241]|giv[242]	_	_
30-32	4907-4908	(	_	_	_	_
30-33	4909-4912	see	_	_	_	_

#Text=Figure 1
31-1	4913-4919	Figure	abstract[243]	new[243]	coref	34-1[250_243]
31-2	4920-4921	1	abstract[243]	new[243]	_	_

#Text=A ) .
32-1	4922-4923	A	_	_	_	_
32-2	4924-4925	)	_	_	_	_
32-3	4926-4927	.	_	_	_	_

#Text=Also , hydrogen bridges from non-ionic protein residues with superabsorber functionalities (
33-1	4928-4932	Also	_	_	_	_
33-2	4933-4934	,	_	_	_	_
33-3	4935-4943	hydrogen	substance|object[245]	new|new[245]	_	_
33-4	4944-4951	bridges	object[245]	new[245]	_	_
33-5	4952-4956	from	object[245]	new[245]	_	_
33-6	4957-4966	non-ionic	object[245]|object[247]	new[245]|giv[247]	coref	35-8[255_247]
33-7	4967-4974	protein	object[245]|substance|object[247]	new[245]|giv|giv[247]	_	_
33-8	4975-4983	residues	object[245]|object[247]	new[245]|giv[247]	_	_
33-9	4984-4988	with	object[245]|object[247]	new[245]|giv[247]	_	_
33-10	4989-5002	superabsorber	object[245]|object[247]|object|abstract[249]	new[245]|giv[247]|giv|new[249]	_	_
33-11	5003-5018	functionalities	object[245]|object[247]|abstract[249]	new[245]|giv[247]|new[249]	_	_
33-12	5019-5020	(	_	_	_	_

#Text=Figure 1
34-1	5021-5027	Figure	abstract[250]	giv[250]	coref	36-1[256_250]
34-2	5028-5029	1	abstract[250]	giv[250]	_	_

#Text=B ) or entrapment of enzyme in superabsorber-bound water residues (
35-1	5030-5031	B	abstract	new	_	_
35-2	5032-5033	)	_	_	_	_
35-3	5034-5036	or	_	_	_	_
35-4	5037-5047	entrapment	event[252]	new[252]	_	_
35-5	5048-5050	of	event[252]	new[252]	_	_
35-6	5051-5057	enzyme	event[252]|substance	new[252]|giv	coref	39-6[271_0]
35-7	5058-5060	in	event[252]	new[252]	_	_
35-8	5061-5080	superabsorber-bound	event[252]|object[255]	new[252]|giv[255]	_	_
35-9	5081-5086	water	event[252]|substance|object[255]	new[252]|new|giv[255]	_	_
35-10	5087-5095	residues	event[252]|object[255]	new[252]|giv[255]	_	_
35-11	5096-5097	(	_	_	_	_

#Text=Figure 1
36-1	5098-5104	Figure	abstract[256]	giv[256]	_	_
36-2	5105-5106	1	abstract[256]	giv[256]	_	_

#Text=C ) can be a possible mode of interaction .
37-1	5107-5108	C	abstract	new	_	_
37-2	5109-5110	)	_	_	_	_
37-3	5111-5114	can	_	_	_	_
37-4	5115-5117	be	_	_	_	_
37-5	5118-5119	a	abstract[258]	new[258]	_	_
37-6	5120-5128	possible	abstract[258]	new[258]	_	_
37-7	5129-5133	mode	abstract[258]	new[258]	_	_
37-8	5134-5136	of	abstract[258]	new[258]	_	_
37-9	5137-5148	interaction	abstract[258]|abstract	new[258]|new	_	_
37-10	5149-5150	.	_	_	_	_

#Text=An ( R )-enantioselective ADH from Lactobacillus brevis ( LB-ADH ) has been shown to be a versatile catalyst for the reduction of a variety of ketones , ranging from aliphatic ketones to benzylic or propargylic ketones .
38-1	5151-5153	An	abstract[261]	giv[261]	coref	42-8[284_261]
38-2	5154-5155	(	abstract[261]	giv[261]	_	_
38-3	5156-5157	R	person|abstract[261]	new|giv[261]	_	_
38-4	5158-5176	)-enantioselective	abstract[261]	giv[261]	_	_
38-5	5177-5180	ADH	abstract[261]	giv[261]	_	_
38-6	5181-5185	from	abstract[261]	giv[261]	_	_
38-7	5186-5199	Lactobacillus	abstract[261]|abstract[262]	giv[261]|giv[262]	_	_
38-8	5200-5206	brevis	abstract[261]|abstract[262]	giv[261]|giv[262]	_	_
38-9	5207-5208	(	_	_	_	_
38-10	5209-5215	LB-ADH	substance	giv	_	_
38-11	5216-5217	)	_	_	_	_
38-12	5218-5221	has	_	_	_	_
38-13	5222-5226	been	_	_	_	_
38-14	5227-5232	shown	_	_	_	_
38-15	5233-5235	to	_	_	_	_
38-16	5236-5238	be	_	_	_	_
38-17	5239-5240	a	substance[264]	giv[264]	ana	39-1[0_264]
38-18	5241-5250	versatile	substance[264]	giv[264]	_	_
38-19	5251-5259	catalyst	substance[264]	giv[264]	_	_
38-20	5260-5263	for	substance[264]	giv[264]	_	_
38-21	5264-5267	the	substance[264]|abstract[265]	giv[264]|new[265]	_	_
38-22	5268-5277	reduction	substance[264]|abstract[265]	giv[264]|new[265]	_	_
38-23	5278-5280	of	substance[264]|abstract[265]	giv[264]|new[265]	_	_
38-24	5281-5282	a	substance[264]|abstract[265]|abstract[266]	giv[264]|new[265]|new[266]	_	_
38-25	5283-5290	variety	substance[264]|abstract[265]|abstract[266]	giv[264]|new[265]|new[266]	_	_
38-26	5291-5293	of	substance[264]|abstract[265]|abstract[266]	giv[264]|new[265]|new[266]	_	_
38-27	5294-5301	ketones	substance[264]|abstract[265]|abstract[266]|substance[267]	giv[264]|new[265]|new[266]|new[267]	coref	38-31[268_267]
38-28	5302-5303	,	substance[264]|abstract[265]|abstract[266]|substance[267]	giv[264]|new[265]|new[266]|new[267]	_	_
38-29	5304-5311	ranging	substance[264]|abstract[265]|abstract[266]|substance[267]	giv[264]|new[265]|new[266]|new[267]	_	_
38-30	5312-5316	from	substance[264]|abstract[265]|abstract[266]|substance[267]	giv[264]|new[265]|new[266]|new[267]	_	_
38-31	5317-5326	aliphatic	substance[264]|abstract[265]|abstract[266]|substance[267]|substance[268]	giv[264]|new[265]|new[266]|new[267]|giv[268]	coref	38-34[269_268]
38-32	5327-5334	ketones	substance[264]|abstract[265]|abstract[266]|substance[267]|substance[268]	giv[264]|new[265]|new[266]|new[267]|giv[268]	_	_
38-33	5335-5337	to	substance[264]|abstract[265]|abstract[266]|substance[267]	giv[264]|new[265]|new[266]|new[267]	_	_
38-34	5338-5346	benzylic	substance[264]|abstract[265]|abstract[266]|substance[267]|substance[269]	giv[264]|new[265]|new[266]|new[267]|giv[269]	_	_
38-35	5347-5349	or	substance[264]|abstract[265]|abstract[266]|substance[267]|substance[269]	giv[264]|new[265]|new[266]|new[267]|giv[269]	_	_
38-36	5350-5361	propargylic	substance[264]|abstract[265]|abstract[266]|substance[267]|substance[269]	giv[264]|new[265]|new[266]|new[267]|giv[269]	_	_
38-37	5362-5369	ketones	substance[264]|abstract[265]|abstract[266]|substance[267]|substance[269]	giv[264]|new[265]|new[266]|new[267]|giv[269]	_	_
38-38	5370-5371	.	_	_	_	_

#Text=It can be used as an isolated enzyme or as a whole-cell catalyst .
39-1	5372-5374	It	substance	giv	coref	39-11[272_0]
39-2	5375-5378	can	_	_	_	_
39-3	5379-5381	be	_	_	_	_
39-4	5382-5386	used	_	_	_	_
39-5	5387-5389	as	_	_	_	_
39-6	5390-5392	an	substance[271]	giv[271]	_	_
39-7	5393-5401	isolated	substance[271]	giv[271]	_	_
39-8	5402-5408	enzyme	substance[271]	giv[271]	_	_
39-9	5409-5411	or	_	_	_	_
39-10	5412-5414	as	_	_	_	_
39-11	5415-5416	a	substance[272]	giv[272]	ana	40-4[0_272]
39-12	5417-5427	whole-cell	substance[272]	giv[272]	_	_
39-13	5428-5436	catalyst	substance[272]	giv[272]	_	_
39-14	5437-5438	.	_	_	_	_

#Text=In particular , its tolerance towards organic solvents is outstanding .
40-1	5439-5441	In	_	_	_	_
40-2	5442-5452	particular	_	_	_	_
40-3	5453-5454	,	_	_	_	_
40-4	5455-5458	its	substance|abstract[274]	giv|new[274]	_	_
40-5	5459-5468	tolerance	abstract[274]	new[274]	_	_
40-6	5469-5476	towards	abstract[274]	new[274]	_	_
40-7	5477-5484	organic	abstract[274]|substance[275]	new[274]|giv[275]	_	_
40-8	5485-5493	solvents	abstract[274]|substance[275]	new[274]|giv[275]	_	_
40-9	5494-5496	is	_	_	_	_
40-10	5497-5508	outstanding	_	_	_	_
40-11	5509-5510	.	_	_	_	_

#Text=The stability depends on several factors , such as the nature of the buffer or solvent additives .
41-1	5511-5514	The	abstract[276]	new[276]	_	_
41-2	5515-5524	stability	abstract[276]	new[276]	_	_
41-3	5525-5532	depends	_	_	_	_
41-4	5533-5535	on	_	_	_	_
41-5	5536-5543	several	abstract[277]	new[277]	_	_
41-6	5544-5551	factors	abstract[277]	new[277]	_	_
41-7	5552-5553	,	abstract[277]	new[277]	_	_
41-8	5554-5558	such	abstract[277]	new[277]	_	_
41-9	5559-5561	as	abstract[277]	new[277]	_	_
41-10	5562-5565	the	abstract[277]|abstract[278]	new[277]|new[278]	_	_
41-11	5566-5572	nature	abstract[277]|abstract[278]	new[277]|new[278]	_	_
41-12	5573-5575	of	abstract[277]|abstract[278]	new[277]|new[278]	_	_
41-13	5576-5579	the	abstract[277]|abstract[278]|substance[279]	new[277]|new[278]|new[279]	_	_
41-14	5580-5586	buffer	abstract[277]|abstract[278]|substance[279]	new[277]|new[278]|new[279]	_	_
41-15	5587-5589	or	abstract[277]|abstract[278]	new[277]|new[278]	_	_
41-16	5590-5597	solvent	abstract[277]|abstract[278]|substance|substance[281]	new[277]|new[278]|new|new[281]	_	_
41-17	5598-5607	additives	abstract[277]|abstract[278]|substance[281]	new[277]|new[278]|new[281]	_	_
41-18	5608-5609	.	_	_	_	_

#Text=In this contribution , the application of a superabsorber-immobilized ADH from L. brevis for an enzymatic reduction of acetophenone ( 1 ) in a flow process is described .
42-1	5610-5612	In	_	_	_	_
42-2	5613-5617	this	abstract[282]	new[282]	_	_
42-3	5618-5630	contribution	abstract[282]	new[282]	_	_
42-4	5631-5632	,	_	_	_	_
42-5	5633-5636	the	event[283]	new[283]	_	_
42-6	5637-5648	application	event[283]	new[283]	_	_
42-7	5649-5651	of	event[283]	new[283]	_	_
42-8	5652-5653	a	event[283]|abstract[284]	new[283]|giv[284]	_	_
42-9	5654-5679	superabsorber-immobilized	event[283]|abstract[284]	new[283]|giv[284]	_	_
42-10	5680-5683	ADH	event[283]|abstract[284]	new[283]|giv[284]	_	_
42-11	5684-5688	from	event[283]|abstract[284]	new[283]|giv[284]	_	_
42-12	5689-5691	L.	event[283]|abstract[284]|person[285]	new[283]|giv[284]|new[285]	_	_
42-13	5692-5698	brevis	event[283]|abstract[284]|person[285]	new[283]|giv[284]|new[285]	_	_
42-14	5699-5702	for	event[283]	new[283]	_	_
42-15	5703-5705	an	event[283]|abstract[286]	new[283]|new[286]	_	_
42-16	5706-5715	enzymatic	event[283]|abstract[286]	new[283]|new[286]	_	_
42-17	5716-5725	reduction	event[283]|abstract[286]	new[283]|new[286]	_	_
42-18	5726-5728	of	event[283]|abstract[286]	new[283]|new[286]	_	_
42-19	5729-5741	acetophenone	event[283]|abstract[286]|substance[287]	new[283]|new[286]|new[287]	_	_
42-20	5742-5743	(	event[283]|abstract[286]|substance[287]	new[283]|new[286]|new[287]	_	_
42-21	5744-5745	1	event[283]|abstract[286]|substance[287]|abstract	new[283]|new[286]|new[287]|new	_	_
42-22	5746-5747	)	event[283]|abstract[286]|substance[287]	new[283]|new[286]|new[287]	_	_
42-23	5748-5750	in	event[283]|abstract[286]	new[283]|new[286]	_	_
42-24	5751-5752	a	event[283]|abstract[286]|event[290]	new[283]|new[286]|new[290]	_	_
42-25	5753-5757	flow	event[283]|abstract[286]|abstract|event[290]	new[283]|new[286]|new|new[290]	_	_
42-26	5758-5765	process	event[283]|abstract[286]|event[290]	new[283]|new[286]|new[290]	_	_
42-27	5766-5768	is	_	_	_	_
42-28	5769-5778	described	_	_	_	_
42-29	5779-5780	.	_	_	_	_
